麻豆传媒

Adding atezolizumab, camrelizumab to chemotherapy improves pCR but not survival endpoints

Study was stopped early due to enrollment issues, but lessons can still be learned

Significant improvement in 5-year distant relapse-free interval with higher risk score

Radiotherapy also resulted in fewer treatment-related adverse events

Nearly identical 5-year outcomes with no surgery, sentinel lymph node biopsy

Study results are "historic," expert says

Lower rates of mortality and cancer recurrence with mastectomy, salpingo-oophorectomy

No invasive cancer increase at 2 years, but editorialists say data don't back active monitoring

However, imlunestrant failed to improve PFS among entire trial population

Triplet therapy may surpass benefits of current "pretty active doublet" therapy, expert says

Two-thirds of patients progression free at 6 months with zanidatamab, palbociclib, fulvestrant

No difference for survival outcomes for annual versus around every 2 years

However, the surgery did reduce risk of contralateral breast cancer

Local recurrence rate of 1% at 5 years in women ages 50-69 with genomically low-risk disease